Author

T. J. Pugh

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Research Focus:cell type annotation· 3 Research Focus:differential expression· 3 Research Focus:drug response / drug discovery· 3 Approach:statistical model· 3 Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1

Frequent Co-Authors

A. J. Mungall· 2 shared A. Nikolic· 2 shared B. Haibe-Kains· 2 shared F. J. Coutinho· 2 shared F. M. Cavalli· 2 shared K. Ellestad· 2 shared M. A. Marra· 2 shared M. D. Taylor· 2 shared

Activity by Year

2018-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. J. Mungall

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Meta-analysis of preclinical pharmacogenomic studies to discover robust and translatable biomarkers of drug response

P. Smirnov, S. K. Nair, F. Abbas-Aghababazadeh, N. Feizi, I. Smith, T. J. Pugh, B. Haibe-Kains

This study identifies 4,338 statistically significant biomarkers of drug response across 8 tissue types and 34 drugs using meta-analysis of preclinical pharmacogenomic studies, with ODC1 showing clinical relevance for Paclitaxel response in breast cancer.

bioRxiv · Oct 22, 2022 · PreprintCancer Biology

Single-cell transcriptional analysis of the immune tumour microenvironment during myeloma disease evolution

D. C. Croucher, L. M. Richards, D. Waller, Z. Li, X. F. Huang, M. Chesi, P. L. Bergsagel, M. Sebag, T. J. Pugh, S. Trudel

This study uses single-cell RNA-sequencing to analyze immune cell changes in myeloma progression and identifies potential therapeutic targets for early intervention.

bioRxiv · Oct 22, 2021 · PreprintCancer Biology

Karyotypic divergence confounds cellular phenotypes in large pharmacogenomic studies

R. Quevedo, N. El-Hachem, P. Smirnov, Z. Safikhani, T. J. Pugh, B. Haibe-Kains

This study identifies discordances in genotypic and karyotypic profiles across pharmacogenomic datasets, highlighting the impact of copy-number variants on drug response and the need for verification of cell line profiles.

bioRxiv · Mar 11, 2019 · PreprintCancer Biology

High-resolution structural genomics reveals new therapeutic vulnerabilities in glioblastoma

M. J. Johnston, A. Nikolic, N. Ninkovic, P. Guilhamon, F. M. Cavalli, S. Seaman, F. J. Zemp, J. Lee, A. Abdelkareem, K. Ellestad, A. Murison, M. M. Kushida, F. J. Coutinho, Y. Ma, A. J. Mungall, , M. Gallo

This study uses high-resolution 3D genome maps to identify CD276 as a therapeutic target in glioblastoma stem cells, showing it can suppress self-renewal.

bioRxiv · Oct 13, 2018Cancer Biology

Subclonal architecture, evolutionary trajectories and patterns of inheritance of germline variants in pediatric glioblastoma

M. Hoffman, A. H. Gillmor, D. J. Kunz, M. J. Johnston, A. Nikolic, K. Karta, J. King, K. Ellestad, N. H. Dang, F. M. Cavalli, M. M. Kushida, F. J. Coutinho, B. Luu, Y. Ma, A. J. Mungall, , M. Gallo

This study examines genetic heterogeneity and evolutionary patterns in pediatric glioblastoma using whole-genome sequencing of germline-tumor pairs, revealing subclonal architecture and complex inheritance mechanisms.

bioRxiv · Oct 12, 2018Cancer Biology